I agree and it seems the FDA likely does too because they already told CRMD they could apply for LPAD. One of the main features of LPAD is smaller shorter trials for an unmet need in a limited population. Any added risk due to shorter smaller trial is assumed out weighed by the limited population and unmet need.
If the FDA knew they would not grant LPAD they would not have told CRMD they could apply for it. CRMD trial was huge and long in duration so it would be shocking to require another trial under LPAD.